Table of Contents Show
Emergent BioSolutions (EBS) has recently made headlines with the announcement of the sale of its travel health business to Bavarian Nordic for up to $380 million, including potential future milestone payments. The sale is expected to enable EBS to sharpen its focus on protecting and enhancing life through its core products and contract manufacturing services businesses. EBS stock provides solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. It also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.
EBS Stock Recent Financial Performance
Currently, EBS is trading at 14.65 with a gain of +1.39 or (+10.48%) in Pre-Market trading. The company’s previous close was 13.15, with an open of 13.18, and a day’s range of 12.87 – 13.36. EBS’s 52-week range is 10.61 – 45.14, and its market cap is 661.518M. The beta (5Y Monthly) is 0.91, the PE ratio (TTM) is 16.78, and the EPS (TTM) is 0.79. The earnings date for EBS is Feb 27, 2023, and the 1y target estimate is 30.50.
EBS is in the healthcare sector and operates in the drug manufacturers industry. Currently, 10.15% of shares are held by all insiders, and 91.09% of shares are held by institutions. There are 298 institutions holding shares.
In terms of recent financial performance, EBS’s revenue for the fiscal year 2021 was $1.79 billion. The company’s cost of revenue was $757.50 million, and its gross profit was $1.04 billion, with a gross profit ratio of 0.58. EBS’s net income for 2021 was $230.90 million, with an EPS of 4.32.
Emergent BioSolutions Sells Travel Health Business
The sale of the travel health business to Bavarian Nordic is a significant development for EBS. Under the terms of the definitive agreement, Bavarian Nordic will acquire the rights to VIVOTIF®, indicated for the active immunization to prevent typhoid fever, and VAXCHORA®, indicated for the active immunization to prevent cholera, as well as the development-stage chikungunya vaccine candidate CHIKV VLP. Bavarian Nordic will also acquire EBS’s manufacturing site in Bern, Switzerland, and development facilities in San Diego, California. Approximately 280 current EBS employees are expected to join Bavarian Nordic as part of the transaction.
The sale of its travel health business builds on EBS’s previously announced strategic prioritization of its medical countermeasure products, such as ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), TEMBEXA® (brincidofovir), RSDL® (Reactive Skin Decontamination Lotion Kit), several anthrax products, and opioid overdose reversal medicine NARCAN® (naloxone HCl) Nasal Spray, and contract development and manufacturing services businesses. Together, these actions will improve profitability and position EBS for steady, sustainable growth over the long term.
Impact of the Sale on Emergent BioSolutions
While the sale of the travel health business to Bavarian Nordic is a positive development for EBS, there are still risks and uncertainties associated with the sale. It remains to be seen how the transaction will impact EBS’s financial position and future prospects.
Industry experts have weighed in on EBS’s recent performance and the impact of the travel health business sale. Some have expressed optimism that the sale will enable EBS to focus on its core products and contract manufacturing
Stock Analysis of EBS
The stock price has experienced significant declines over the past several years, including a 70.42% decline over the past year and a 79.21% decline over the past three years. However, the stock has experienced a year-to-date price change of 10.32%, and the one-day price change is currently 0.84.
EBS Stock is expected to report revenues ranging from $2.22 billion to $3.32 billion for the year ending December 31, 2023, with an estimated revenue average of $2.77 billion. The estimated EPS average is 12.72, with a range from $10.17 to $15.27. The company’s financial ratios indicate that it has a debt-to-equity ratio of 1.01 and a price-to-earnings ratio of 12.37. The company also has a quick ratio of 1.61 and a return on equity of 0.03.
In conclusion, EBS stock is a pharmaceutical company that focuses on developing and commercializing therapies for rare diseases. The company has shown strong revenue growth and profitability in recent years, although it has experienced significant declines in its stock price in the last few years.
The company is projected to see revenue growth in the upcoming year, although estimates for other financial metrics are mixed. The company has a solid balance sheet with manageable debt levels, although its stock valuation ratios are relatively low compared to its peers. Investors considering EBS should carefully evaluate the company’s financial metrics and industry trends before making investment decisions.